Spatial Distance Correlates With Genetic Distance in Diffuse Glioma

Evan D. H. Gates 1,2†, Jie Yang 2,3†, Kazutaka Fukumura 4†, Jonathan S. Lin 1,5,6, Jeffrey S. Weinberg 7, Sujit S. Prabhu 7, Lihong Long 8, David Fuentes 1, Erik P. Sulman 3, Jason T. Huse 4,9 and Dawid Schellingerhout 10*

1 Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2 Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center UTHHealth, Houston, TX, United States, 3 Department of Radiation Oncology, NYU Langone School of Medicine, New York, NY, United States, 4 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 5 Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, United States, 6 Department of Bioengineering, Rice University, Houston, TX, United States, 7 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 8 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 9 Department of Pathology and Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Background: Treatment effectiveness and overall prognosis for glioma patients depend heavily on the genetic and epigenetic factors in each individual tumor. However, intra-tumoral genetic heterogeneity is known to exist and needs to be managed. Currently, evidence for genetic changes varying spatially within the tumor is qualitative, and quantitative data is lacking. We hypothesized that a greater genetic diversity or “genetic distance” would be observed for distinct tumor samples taken with larger physical distances between them.

Methods: Stereotactic biopsies were obtained from untreated primary glioma patients as part of a clinical trial between 2011 and 2016, with at least one biopsy pair collected in each case. The physical (Euclidean) distance between biopsy sites was determined using coordinates from imaging studies. The tissue samples underwent whole exome DNA sequencing and epigenetic methylation profiling and genomic distances were defined in three separate ways derived from differences in number of genes, copy number variations (CNV), and methylation status. We also derived quantitative linear relationships between physical and genomic distances.

Results: Of the 31 patients recruited to the trial, 23 were included in DNA methylation analysis, for a total of 71 tissue samples (14 female, 9 male patients, age range 21–80). Samples from an 8 patient subset of the 23 evaluated patients were further included in whole exome and copy number variation analysis. The physical (Euclidean) distance between biopsy sites was determined using coordinates from imaging studies. The tissue samples underwent whole exome DNA sequencing and epigenetic methylation profiling and genomic distances were defined in three separate ways derived from differences in number of genes, copy number variations (CNV), and methylation profiles.

Citation: Gates EDH, Yang J, Fukumura K, Lin JS, Weinberg JS, Prabhu SS, Long L, Fuentes D, Sulman EP, Huse JT and Schellingerhout D (2019) Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Front. Oncol. 9:676. doi: 10.3389/fonc.2019.00676

*Correspondence: Dawid Schellingerhout dawid.schellingerhout@mdanderson.org
Jason T. Huse jhuse@mdanderson.org
†These authors have contributed equally to this work
INTRODUCTION

Gliomas are thought to be genetically heterogeneous within a single specimen, as manifested by spatial morphological diversity observed on imaging. Genetic analyses are increasingly important in the delineation of glioma subgroups with distinct clinical behavior, as evidenced by the strong influence of genomic classifiers in the WHO 2016 grading system (1). Previous work has shown that biopsies taken from non-representative regions of tumor can produce errors in histopathological grading (2), and while modern image guidance may improve histopathological accuracy (3, 4), there are strong suggestions from the literature that genetic heterogeneity may also be underrepresented by standard surgical sampling (5, 6). Additionally, we know from work in other tumors that genomic signatures can vary depending on regional sampling (7).

If, therefore, molecular heterogeneity varies as a function of location in space, then it is reasonable to hypothesize that such variability might correlate with physical (Euclidean) distance between biopsy sites. A formal relationship between Euclidean and molecular distance per se has not (to our knowledge) been described for glioma. In this study, we seek to address this gap in knowledge, both qualitatively and with a quantitative statistical assessment.

To do so, we obtained multiple sets of stereotactic biopsies in previously untreated glioma patients, carefully noted the physical coordinates of each sample, and calculated the Euclidean distances between each pair of samples within a single tumor. Multidimensional genomic analysis was then performed on each sample, and distinct measures of genomic distance were derived from: (1) mutation number, (2) copy number variation, and (3) the extent of CpG island methylation. We found that in each case, meaningful and positive correlations were present between Euclidean and genetic distance.

METHODS

Biopsy Collection

Our study retrospectively analyzed glioma tissue samples collected as part of an IRB approved, HIPAA-compliant clinical trial protocol (NCT03458676). All subjects gave written informed consent in accordance with the Declaration of Helsinki. Biopsies were collected from previously untreated adult (>18 years old) patients with primary glioma immediately prior to tumor resection. Each patient underwent pre-surgical MRI within 3 days prior to craniotomy. During surgery, two or more image-guided biopsies were collected from each patient. The biopsy locations were chosen based on one or more findings in pre-operative MRI including contrast enhancement, reduced diffusivity, or increased cerebral blood flow. This approach mimics clinical workflow and targets areas likely to harbor malignant tumor tissue. Samples were collected using either a side-cutting, Nashold-type, image-guided biopsy needle (0.9 mm width and 10 mm side port) or by image-registered surgical biopsy forceps based on surgeon preference and patient anatomy. Samples were collected before tumor resection in order to minimize brain shift and we estimate the variance in the distance measurements based on the recorded image coordinates to be <2 mm. Tissue samples were immediately placed on ice for transport to a pathology lab where the tissue was frozen in OCT until analysis.

Biopsy Euclidean Distance

At the time of the biopsy collection, we recorded the image coordinates of the instruments using the surgical navigation software. The distance between separate biopsy sites $i$ and $j$ is calculated by the Euclidean distance of the captured 3D coordinates $(x_i, y_i, z_i)$ and $(x_j, y_j, z_j)$ (Figure 2). When possible for needle biopsies, the “shallow” and “deep” ends of the cylindrical specimens were divided. These specimens were analyzed separately with a distance of 5 mm assigned to the two parts of the divide sample, based on the needle geometry. The exact geometry is illustrated in Supplementary Figure S2.

DNA Extraction

Using light microscopy, each sample was microscopically confirmed to be comprised of tumor before DNA extraction. Percent wise quantification was not attempted due to the small amount of tissue in each sample. DNA was extracted from frozen biopsies and matched normal white blood cells (WBCs) using QIAamp DNA Mini Kit (Qiagen), and DNA concentrations were measured with Qubit fluorometer (Thermo Fisher Scientific).

Whole-Exome Sequencing

Between 200 and 1,000 ng of DNA were used for enrichment of all exonic fragments with SureSelect Human All Exon V6 (Agilent Technologies), followed by massively parallel sequencing on HiSeq4000 platform (Illumina) using 75-bp paired-end option. For the validation of somatic mutations identified by the HiSeq platform, custom PCR primer panels corresponding to the mutations were made with Ion AmpliSeq Designer. The libraries were prepared with Ion AmpliSeq Library Kit Plus (Thermo Fisher Scientific) according to the manufacturer’s protocol, and
then subjected to Ion Proton sequencing (Thermo Fisher Scientific). Where available, we estimated tumor cellularity and ploidy using the whole-exome data and the sequenza (8). This confirmed the tumor content identified microscopically.

**Mutation Count Genetic Distance**

With the whole-exome sequencing (WES) fastq files, we used the BWA-MEM (9) software for read mapping. With the bam files, we used MuTect2 (10) software to call genetic variations between tumor samples and blood control samples and used ANNOVAR (11) to annotate the specific mutations (pseudocode provided on Github).1 We then filtered the resulting mutations based on the following criteria: (1) mutations must be located in exonic regions; (2) mutation function must be frameshift deletion, frameshift insertion, non-synonymous SNV, stopgain or stoploss; (3) reference read count, the read having same base call as reference, must be ≥10; (4) alternative read count, the reads detected as mutations, must be ≥8; and (5) the alternative read frequency must be ≥0.1. These filters ensure the mutations are real, not statistical artifacts, and that they likely lead to molecular tumor changes such as reduced expression levels, truncated proteins, or errors in DNA transcription and translation. The mutation count genetic difference between samples from the same tumor in one patient was measured using the Jaccard distance (12).

\[ d_{\text{Jaccard}} = \frac{\sum (P_i - Q_i)^2}{\sum P_i + \sum Q_i - \sum (P_i * Q_i)} \]

Where \( P_i \) and \( Q_i \) are the alternative allele frequency for the \( i \)th mutation. The mutation count genetic distance between samples is small when the gene mutations are present in both samples and maximum when the sets of mutations are disjoint. Pearson correlation coefficients were calculated between the number of genes/mutation genetic distance and the Euclidean distance for all available biopsy pairs.

**Copy Number Variation Genetic Distance**

Copy number variations (CNV) for paired biopsies were obtained using WES data with CNVKit (13), which has high CNV calling accuracy (14) and can infer information in uncovered intron regions. With the segmentation information for each biopsy, we combined all break points available from all biopsies, created a list of CNV events, and assigned the corresponding log2 ratio value to each event and each biopsy. The CNV distance was calculated using the Canberra distance

\[ d_{\text{Canberra}} = \sum \frac{|P_i - Q_i|}{P_i + Q_i} \]

Where \( P_i \) and \( Q_i \) are the log ratio values of the first and second samples at event \( i \) (12) between paired biopsies from the same patients. The Canberra distance is effectively the L1 distance but scaled at each value by the average signal of the samples. This normalizes the differences so that samples with larger relative absolute difference will be a greater distance apart under this metric. So, CNV distance is a measure of the total amount of DNA variation between samples. Also note that the distance between a sample and itself is zero. Pearson correlation coefficients were calculated between the CNV distance and the Euclidean distance for each biopsy pair.

**Methylation Distance**

DNA was subjected to bisulfite conversion with EZ DNA Methylation-Gold Kit (Zymo Research), and analyzed for methylation profiling using Infinium Methylation EPIC Beadchip and iScan (Illumina). We evaluated differences in DNA methylation as a way to quantify the epigenetic distance between samples and investigate correlation with physical distance. Raw DNA methylation data were processed with default pre-processing steps in UniD (15) as implemented in R. Samples with more than 10% of values missing and probes with more than 3 missing values were excluded. The isocitrate dehydrogenase (IDH) mutation status for each sample was predicted using UniD predictive models (15). The methylation level was represented as a β value [methylated signal divided by the sum of methylated and unmethylated signal (16)]. We first applied unsupervised clustering and t-distributed stochastic neighbor embedding (t-SNE) (17) analysis with the top 200 and 500 probes with the highest median absolute deviation (MAD) values across all samples. Then, using only the most variant probes, we removed probes that are likely uninformative and only reduce statistical power (18). In order to calculate the methylation distance between biopsies pairs from the same patients, we used the top 500 probes with highest variance within each patient to calculate the L1 distance:

\[ d_{L1} = \sum_i |P_i - Q_i| \]

Where \( P_i \) is the \( i \)th β value of the first sample in the pair and \( Q_i \) is the \( i \)th β value of the second sample in the pair (12). The L1 distance metric measures the total variation in methylation values and identical profiles have zero distance. Since the β values are already normalized as the sum of methylated and unmethylated signal, we used the standard L1 distance metric rather than the Canberra distance used for CNV genetic distance. The correlation between the methylation distance and Euclidean distance was measured with the Pearson correlation coefficient.

**RESULTS**

In total, 31 patients were recruited between 2013 and 2016. Patients with no tissue harvest due to surgical complexity, cardiac issues, or technical difficulties or patients with insufficient tissue for downstream molecular analysis were excluded from our study cohort (n = 8) (Figure 1A) leaving 23 patients with 71 biopsies. After exclusions (4 samples) for ambiguous imaging coordinates, 67 samples from 23 patients were subjected to global methylation array-based profiling (Figure 1C). Seventeen of these samples from 8 patients were processed for WES
31 patients were recruited between 2013 and 2016. Five patients had no tissue harvest due to surgical complexity (n = 3), cardiac issues, or technical difficulties and three patients had no sufficient tissue. In total, eight patients were excluded from the cohort. Among the remaining patients, only eight patients had normal blood samples available for whole-exome sequencing and one of those patients only had a single sample sequenced. Based on the mutation calls, one patient was excluded due to abnormally high mutation burden (TMB). The remaining 13 biopsies from 6 patients constitute 8 biopsy pairs for mutation genetic distance. After excluding samples without image coordinates, we have 67 samples from 23 patients for methylation profiling. One sample was excluded from methylation analysis due to poor data quality: 12.85% of available probes returned missing values. In summary, 66 samples from 42 unique image guided biopsy sites in 23 patients were available for methylation data analysis, comprising 77 unique biopsy pairs. The specific patients included in each analysis is available in Table 1. These patients were selected because patient-matched blood samples were retrospectively available for somatic DNA assessment thanks to an institutional tumor banking initiative. A summary of the patient demographic information is given in Table 1. Of the 67 total samples in the final analysis, 46 samples were shallow/deep pairs from needle biopsy, 4 were single samples from needle biopsy, 15 were single samples from forceps biopsy, and 2 were a shallow/deep pair collected from the same spatial location using forceps.

Genomic and physical distances were only calculated on an intra-tumor basis, meaning samples were not compared between patients, but only to other samples in the same patient/tumor.

### Mutation Count Genetic Distance

WES was performed to identify gene mutations in the biopsy tissue samples. The mean coverage was 117 and 103 for tumor tissues and WBCs, respectively. We used the MuTect2 (10) and ANNOVAR (11) for somatic mutation calling and annotation. After filtering mutations, we identified a total of 257 single nucleotide variants (SNVs) and 19 insertions/deletions (indels) in our final 14 tissue samples analyzed.

In further examining the profiles of three biopsies (P12S1, P12S2, and P12S3) from one patient (patient 12), we found significantly higher mutation calls than in the other patients. Even after applying mutation filters, we found patient 12 had on average 2438 mutations per biopsy while all other patients/samples averaged 22 mutations per biopsy. In published literature (19), the median mutation rate per million base (Mb) is <1 for lower grade gliomas. So, the median mutation number for the whole exome (about 30 Mb) is <30. Therefore, we believe these three biopsies show hypermutation. We eliminated the possibility of a mismatched blood sample by comparing the non-conserved long insertion sequence between the blood and tumor samples, which were found to be consistent. Further review of this case revealed a prominent history of cancer in the patient’s family, suggesting a fundamentally distinct mechanism of tumor evolution from those utilized in the remaining cohort. For these reasons, we excluded these samples from mutation count genetic distance analysis (Figure 1B), leaving 14 biopsies in 7 patients for analysis.

A total of 74 somatic mutations identified in our initial WES were then validated by focused Ion Proton...
TABLE 1 | Patient demographic information.

| Pt # | # biopsy samples | # blood samples | # sample pairs | Age | Sex | Primary diagnosis | Clinical information | Test applied |
|------|------------------|-----------------|----------------|-----|-----|-------------------|----------------------|--------------|
| 1    | 3                | 1               | 3              | 36  | F   | OA                | II                   | Codel WT Yes Yes |
| 2    | 2                | 0               | 1              | 25  | F   | Anaplastic Diffuse Glioma | III                  | Codel Mut Yes No |
| 3    | 2                | 0               | 1              | 21  | F   | Anaplastic Diffuse Mixed OA | III                  | Codel Mut Yes No |
| 4    | 6                | 0               | 10             | 26  | F   | GB                | IV                   | Neg Mut Yes No   |
| 5    | 4                | 0               | 6              | 75  | F   | Diffuse Astrocytoma | II                   | Neg WT Yes No   |
| 6    | 2                | 0               | 1              | 56  | F   | Diffuse Glioma    | II                   | Neg Mut Yes No   |
| 7    | 4                | 0               | 6              | 54  | F   | GB                | IV                   | Neg WT Yes No   |
| 8    | 4                | 0               | 6              | 45  | M   | Anaplastic Astrocytoma | III                  | Neg WT Yes No   |
| 9    | 4                | 0               | 6              | 28  | M   | OD                | II                   | Codel Mut Yes No |
| 10   | 3                | 0               | 3              | 30  | F   | Anaplastic Astrocytoma | III                  | Neg Mut Yes No   |
| 11   | 2                | 0               | 1              | 62  | M   | GB                | IV                   | Neg WT Yes No   |
| 12   | 3                | 1               | 3              | 80  | M   | GB                | IV                   | Neg WT Yes No   |
| 13   | 2                | 0               | 1              | 44  | M   | Anaplastic Astrocytoma | III                  | Neg Mut Yes No   |
| 14   | 6                | 0               | 15             | 55  | F   | OD                | II                   | Codel Mut Yes No |
| 15   | 2                | 1               | 1*             | 67  | M   | GB                | IV                   | Neg WT Yes Yes  |
| 16   | 2                | 1               | 1              | 32  | M   | OD                | III                  | Codel Mut Yes Yes |
| 17   | 2                | 1               | 1              | 66  | M   | Diffuse Astrocytoma, GB | IV                   | Neg Mut Yes Yes |
| 18   | 2                | 0               | 1              | 41  | F   | Anaplastic OD     | III                   | Codel Mut Yes No |
| 19   | 2                | 0               | 1              | 58  | F   | Diffuse Astrocytoma, GB | IV                   | Neg WT Yes No   |
| 20   | 2                | 1               | 1              | 35  | F   | OD                | II                   | Codel Mut Yes Yes |
| 21   | 2                | 1               | 1              | 49  | F   | GB                | IV                   | Neg WT Yes Yes  |
| 22   | 2                | 1               | 1              | 32  | M   | Anaplastic Astrocytoma | III                  | Neg Mut Yes Yes |
| 23   | 4                | 0               | 6              | 39  | F   | Diffuse Astrocytoma | II                   | Neg Mut Yes No   |

List of each patient included in the final analysis. EPIC indicates DNA methylation EPIC array was performed on that patient’s samples (for methylation genetic distance) and WES indicated whole-exome sequencing (for mutation and copy number variation genetic distance). Sample pairs refers to the number of biopsy sample pairs that were available to calculate spatial and genetic distance. Patient age, sex, primary diagnosis, WHO grade, 1p/19q, and IDH mutation status are listed for reference. GB, Glioblastoma; OD, oligodendroglioma; OA, oligoastrocytoma. *WES only applied to one of two samples due to insufficient tumor content in one sample. EPIC methylation assay was performed on both samples.

sequencing, yielding a concordance rate of 100% (74/74 mutations, Supplementary Table S1 with primer sequences in Supplementary Table S2). Confident in the quality of our sequencing data, we proceeded to determine the genetic distance as measured by mutation count between patient-matched samples for our remaining pairs as a function of number of distinct mutations. Similar approaches have been applied in recent work (20). We then correlated mutation count genetic distance to Euclidean distance and found a strong correlation (Pearson correlation coefficient = 0.63, p = 0.091) (Figure 2), supporting the notion that as the physical distance between biopsy samples increases, so too does the number of mutated genes. Indeed, some of the most closely clustered samples (Patient 1) by Euclidean distance (5 mm) exhibited only one distinct mutation whereas two samples biopsied 21 mm apart (Patient 22) had 36 distinct mutations between them. On average a one unit increase in mutation count genetic distance unit was equivalent to an increased Euclidean distance of 0.6 mm, and 10 mm of additional Euclidean distance was equivalent to 17 additional mutation counts. The equation of the best fit regression line was: Genetic count distance = −11.6 + 1.7· Euclidean distance in mm.

Using the three samples from patient 1 as unique samples for further exploration, the hierarchical structure between biopsies was investigated (Figure 2). By comparing mutation calls among biopsies, we found that all three samples shared 10 common mutations, while P1S1 or P1S3 each had one additional distinct mutation (Figure 2). Finally, the allele frequency of mutation calls (Figure 2) were generally higher for the shared mutations between the three samples than for the private mutations, suggestive of sub-clonality within independently evolving tumor clones.

Copy Number Variation Genetic Distance

Copy number variation (CNV) for each biopsy was derived from WES data using CNVkit and visualized with Integrative Genomics Viewer (IGV, version 2.4.8) (21, 22) (Figure 3A). We obtained 255 CNV events after combining all break points available. WES data also estimated cellularity to be >50% for a majority of samples used in CNV analysis (Supplementary Table S3). Reassuringly, we found that our data recapitulated well-known glioma-associated patterns such as 1p/19q co-deletion and co-incident 7-gain/10-loss,
characteristic of IDH-mutant oligodendroglioma and IDH-wild type glioblastoma, respectively (Table 1).

Using the log2 ratio value as input, CNV distance was calculated between each biopsy pair. Since the algorithm inferring CNV using WES data relies on the read counts instead of mutation calls, we included the hypermutated case of patient 12 in our CNV analysis (Figure 3C). We compared CNV distance with Euclidean distance for each paired set of biopsy specimens and once again obtained a strong correlation (Pearson correlation coefficient $r = 0.65$, $p = 0.04$, Figure 3B). Moreover, linear regression between CNV distance and Euclidean distance (slope constant was approximately 6.8 log2 CNV per mm) showed the same trend as was seen between mutation count genetic distance and Euclidean distance. IDH mutant and wild-type samples both demonstrated the same general relationship between CNV distance and Euclidean distance. On average 10 mm additional distance increased the CNV distance by 68.4 units. Each unit of CNV distance corresponded to about 0.15 mm Euclidean distance. The equation of the best fit regression line is: $\text{CNV distance} = -93.8 + 6.9 \times \text{Euclidean distance in mm.}$

**Methylation Genetic Distance**

After data pre-processing with the UniD algorithm (see materials and methods), one sample was excluded due to high probe fail percentage (>10%) (Figure 1). Unsupervised hierarchical clustering of the remaining 500 probes and 66 samples delineated two subgroups within the cohort as evidenced by a heatmap (Figure 4, Supplementary Figure S1). The strong separation of the two clusters was further illustrated by t-SNE analysis and visualization (Figure 4). The composition of the two clusters showed a well-established concordance to IDH mutational status (23) (Supplementary Table S4).

Methylation distance was then independently calculated between all possible biopsy pairs from each patient using the L1 distance between the values of the top 500 most variant methylation probes. Comparing these findings with Euclidean distance once again revealed a significant correlation (Pearson correlation coefficient 0.35, $p = 0.002$) (Figure 4). The abundance of sample pairs at a Euclidean distance of 5 mm is due to the shallow and deep portions of the same biopsy specimen, separated from each other by 5 mm, being analyzed separately (Supplementary Figure S2). The methylation distance between
FIGURE 3 | Whole Exome Sequencing (WES) derived copy number variations (CNV) distance. (A) CNV shown in Integrative Genomics Viewer (IGV). Chromosomes are labeled at the top of the panel and sorted in order from chromosome 1 to chromosome Y. Each row represents one sample identified by patient number (P) and sample number (S). The color blocks show the CNV log2 ratio value: blue indicated loss of copies while red indicated amplification. For regions with the same CNV across samples (solid column of blue marked with red arrows) there is no information across all samples. (B) CNV distance showed high correlation with the Euclidean distance between biopsy pairs from the same patient (Pearson $r = 0.65$). Pairs were drawn with color indicating IDH mutation status. (C) The paired sample details based on the label in (B). Each sample is labeled by patient number (P) and sample number (S).

these shallow/deep pairs spanned the entire dynamic range, a finding not seen for other measures of molecular distance (see above). This discrepancy may be due to greater fluctuation in the DNA methylation profile between samples compared to mutational or copy number variation or may be due to the increased number of samples available for methylation analysis. Regardless, there is a significant correlation (correlation coefficient $= 0.35$, $p = 0.002$) between methylation distance and Euclidean distance and the minimum methylation distance between samples increased substantially with a Euclidean distance above about 2 cm. Based on the best-fit regression line we estimate an increase in the methylation distance of about 1.8 per 10 mm Euclidean distance, with each unit of methylation genetic distance corresponding to about 5.6 mm of Euclidean distance. The best-fit regression line equation was: Methylation genetic distance = 5.27 + 0.18. Euclidean distance in mm. The relation between methylation genetic distance and Euclidean distance is fairly consistent between samples from IDH wild-type and IDH mutant tumors as seen visually in Figure 4. The correlation remains statistically significant even when only samples with similar IDH mutation or 1p/19q co-deletion status are considered. See the Supplementary Figures S3, S4 for details.

DISCUSSION

Many recent studies have documented the heterogeneity characterizing malignant glioma (24–26). Delineating the molecular mechanisms driving this heterogeneity remains an active area of investigation, as does the optimization of techniques for its non-invasive assessment. In this study, we aimed to establish informative and quantitative links between heterogeneity and spatial distance in a small glioma patient cohort. Among the most basic measures of spatial variability is simple Euclidean distance, and we found strong correlations between this metric and multiple assessments of molecular distance for distinct genomic/epigenomic variables. Two of these “molecular distances” were based on some form of total variation, or $L_1$ distance, an additional similarity, and the third (mutation count genetic distance) used a sum-of-squared distances. Future work may incorporate image data to develop a more complex measure of “radiographic distance” to complement physical distance. Our findings confirm prior work showing that gliomas exhibit spatial variability in their genomic signatures dependent on precise biopsy site location (5, 6, 24, 27). Moreover, they establish, for our limited patient population, a set of correlation constants for the various measures of molecular distance and...
A proposed mechanism for tumor heterogeneity is that distinct molecular characteristics become apparent in cancer cell clones as they distribute themselves across a given tumor mass over time (28, 29). While our present study does not investigate this mechanism directly, it is one potential explanation for the correlation between spatial and genetic distance. Whether acquired molecular alterations actively drive cellular motility as a rule, however, remains less certain. Recent literature suggests that branching mutational profiles of multiple tumor samples are due in part to differences in selective pressures (6, 7, 29), from environmental factors such as hypoxia (30). Such constraints could fundamentally drive molecular evolution as a means to escape suboptimal microenvironments. However, simple expansion of a tumor mass would also be expected to passively drive clones apart that, over time, would acquire increasing molecular distinctiveness.

This proposed mechanism does not account for hypermutated cases such as the patient we discussed previously. Given that the patients in our study were previously untreated, we can exclude the possibility of these mutations being caused by
alkylating chemotherapeutic agents. In the absence of prior treatment the hypermutation status suggests an underlying germ line mutation, although our analysis precludes certainty. This is further supported by the patient’s strong family history of cancer (31, 32).

Although our results show substantial differences in the number of mutations between samples from the same patient (Supplementary Table S5), we found that some root-level carcinogenic mutations like IDH1 were consistently present or absent in all samples from a given patient (Supplementary Table S4). Genomic findings thus support a branched evolution pattern, where some genetic events, in particular IDH1 mutations, are fundamental, required for tumorigenesis and are thus present in all samples. Accordingly, these alterations are truncal, with more unusual mutations relegated to sub-clonal events in selected populations (5, 6). These early, required mutations, tend to be diagnostically important, as reflected by the inclusion of IDH1 in the WHO grading criteria (1). These findings also reflect multiple published reports on clonal evolution within malignant glioma (5, 27).

As the classification and prognosis of gliomas is substantially influenced by genomic features, we suspect that the specific relationship between spatial and molecular distance might depend on the grade and type of the glioma. Within our sample set, additional subgroupings could be made based on established and prognostically relevant molecular stratifiers such as IDH mutation status and MGMT promotor methylation. However, our patient population is not large enough to examine distinctions within these smaller subgroups with sufficient statistical power. Nevertheless, our results using a combined glioma population across grades and subtypes suggests the positive and linear relationship between spatial and genetic distance is a characteristic of gliomas in general.

The concept of genetic heterogeneity is not novel, but our work is the first attempt (to our knowledge) to formally quantitate the relationship between spatial and genetic distances. We chose to use the simplest measure of correlation between spatial and genetic distance (i.e., linear) as the initial avenue of investigation. More complex methods of quantitating this relationship in the future may provide better correlation or interpretability. We also look to future investigations to elucidate the undoubtedly complex relationships between glioma subtypes, grades, and diverse genomic selectors, and the spatial distribution of genomic heterogeneity.

We propose that the further exploration of such genomic-spatial relationships in clinical trials similar to the current study, is justified. Establishing first the fundamental, and later on, more sophisticated imaging-genomic correlates, will put the field of imaging genomics on a firm scientific footing, and develop it into something that could be made useful for patient care.

**CONCLUSION**

The genetic heterogeneity of gliomas is correlated to physical distance within individual tumors, as confirmed by quantitative relationships using multiple independent methods. These findings likely support a diverging clonal evolutionary model of glioma expansion.

**DATA AVAILABILITY**

The datasets for this manuscript are not publicly available because analysis as part of a larger study is still ongoing. Requests to access the datasets should be directed to DS, dawid.schellingerhout@mdanderson.org.

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of The University of Texas MD Anderson Cancer Center IRB with written informed consent from all subjects in accordance with the Declaration of Helsinki. The protocol was approved by The University of Texas MD Anderson Cancer Center IRB.

**AUTHOR CONTRIBUTIONS**

EG, JY, KF, JL, JW, SP, DF, ES, JH, and DS: study design. EG, JY, KF, JW, SP, LL, DF, JH, and DS: data collection, analysis, and interpretation. EG, JY, KF, JL, DF, ES, JH, and DS: manuscript writing. EG, JY, JH, and DS: figures.

**FUNDING**

UT MD Anderson Institutional Research Grant (DS). UT MD Anderson Clinical Research Trial Support (DS). UT MD Anderson Diagnostic Imaging Clinical Research Committee Imaging costs support (DS). UT MD Anderson Sequencing and Microarray Facility Core grant CA016672(SMF) provided support for exome sequencing. EG is supported by a fellowship from the Gulf Coast Consortia on the NLM Training Program in Biomedical Science and Data Science T15LM007093.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2019.00676/full#supplementary-material

**REFERENCES**

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1

2. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management
Spatial Genetic Distance in Glioma

3. McGirt MJ, Villavicencio AT, Bulsara KR, Friedman AH. MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. Surg Neurol. (2003) 59:279–83. doi: 10.1016/S0081-5534(03)00048-X

4. Gates ED, Lin JS, Weinberg JS, Hamilton J, Prabhu SS, Hazle JD, et al. Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging. Neuro Oncol. (2019) 21:527–36. doi: 10.1093/neuonc/noz004

5. Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee JH, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. (2017) 49:594–9. doi: 10.1038/ng.3806

6. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. (2015) 47:458–68. doi: 10.1038/ng.3273

7. Gerlinger M, Rowan AJ, Horswill S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. (2012) 366:883–92. doi: 10.1056/NEJMoa1113205

8. Eklund AC, Marquard AM, Favero F, Krzystanek M, Birkbak NJ, Li Q, et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol. (2014) 26:64–70. doi: 10.1093/annonc/mdu479

9. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Nat Biotechnol. (2009) 25:19–25. doi: 10.1038/nbte850

10. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. (2013) 31:213–9. doi: 10.1038/nbt.2514

11. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. (2010) 38:e164–e. doi: 10.1093/nar/gkp603

12. Cha SH. Comprehensive survey on distance/similarity measures between probability density functions. Int J Math Models Method Appl Sci. (2007) 1:300–7. Available online at: http://www.naun.org/main/NAUN/jmmmas/2007.htm

13. Talevich E, Shain AH, Bottom T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. (2016) 12:e1004873. doi: 10.1371/journal.pcbi.1004873

14. Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, et al. Gene copy number estimation from targeted next-generation sequencing of prostate cancer biopsies: analytic validation and clinical qualification. Clin Cancer Res. (2017) 23:6070–7. doi: 10.1158/1078-0432.CCR-17-0972

15. Yang J, Wang Q, Long L, Ezhilarasan R, Sulman E. UnIDr: unified and integrated diagnostic pipeline for malignant gliomas based on DNA methylation data. Cancer Res. (2017) 77(13 Suppl):3448. doi: 10.1158/0166-6895.AM2017-3348

16. Bock C. Analysing and interpreting DNA methylation data. Nat Rev Genet. (2012) 13:705–19. doi: 10.1038/nrg2973

17. van der Maaten LJP, Hinton GE. Visualizing high-dimensional data using t-SNE. J Mach Learn Res. (2008) 9:2579–605. Available online at: http://www.jmlr.org/papers/volume9/vandermaaten08a/vandermaaten08a.pdf

18. Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. (2014) 8:798–806. doi: 10.1016/j.celrep.2014.06.053

19. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. (2013) 500:415–21. doi: 10.1038/nature12477

20. Gerlinger M, Horswill S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genetics. (2014) 46:225. doi: 10.1038/ng.2891

21. Robinson JT, Thorvalsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. (2011) 29:24–6. doi: 10.1038/nbt.1754

22. Thorvalsdottir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. (2013) 14:178–92. doi: 10.1093/bib/bbs017

23. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. (2012) 483:479. doi: 10.1038/nature10866

24. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. (2013) 110:4009–14. doi: 10.1073/pnas.1219747110

25. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. (2008) 455:1051–6. doi: 10.1038/nature07385

26. Patel AP, Tirosh I, Trombetta JI, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. (2014) 344:1396. doi: 10.1126/science.1254257

27. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. (2014) 343:189. doi: 10.1126/science.1239947

28. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. (2012) 72:4875. doi: 10.1158/0008-5472.CAN-12-2217

29. Greaves M, Maley CC. Clonal evolution in cancer. Nature. (2012) 481:306. doi: 10.1038/nature10762

30. Zazgag D, Zhong H, Scalziitti Joanne M, Laughner E, Simons Jonathan W, Semenza Gregg L. Expression of hypoxia-inducible factor 1α in brain tumors. Cancer. (2000) 88:2606–18. doi: 10.1002/1097-0142(20000601)88:11<2606::AID-CNC253>3.0.CO;2-N

31. van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. (2015) 129:597–607. doi: 10.1007/s00401-015-1403-6

32. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, et al. Comprehensive analysis of hypermutation in human cancer. Cell. (2017) 171:1042–56.e10. doi: 10.1016/j.cell.2017.09.048

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Gates, Yang, Fukumura, Lin, Weinberg, Prabhu, Long, Fuentes, Sulman, Huse and Schellingerhout. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.